Aulakh C S, Hill J L, Murphy D L
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland.
J Pharmacol Exp Ther. 1992 Nov;263(2):588-95.
Administration of m-chlorophenylpiperazine [m-CPP, a serotonin (5-HT) agonist] to rats increases plasma concentrations of prolactin and corticosterone. Pretreatment with various doses of ritanserin (5-HT1C/5-HT2 antagonist), ICS 205-930 and MDL-72222 (5-HT3 antagonists), iodocyanopindolol or CG361A (beta adrenoceptor antagonists) and spiperone (5-HT1A/5-HT2 antagonist) did not attenuate m-CPP-induced increases in plasma concentrations of prolactin. In contrast, pretreatment with various doses of metergoline (5-HT1/5-HT2 antagonist), propranolol (beta adrenoceptor antagonist that also has binding affinity for 5-HT1A, 5-HT1B and 5-HT1C sites), mesulergine and mianserin (5-HT1C/5-HT2 antagonists) attenuated m-CPP-induced increases in plasma prolactin. On the other hand, m-CPP-induced increases in corticosterone concentrations were attenuated only by pretreatment with a low dose of mianserin and a high dose of spiperone. When administered without m-CPP, metergoline, mesulergine, ritanserin, ICS 205-930 and high doses of mianserin, spiperone and propranolol increased plasma corticosterone secretion. On the other hand, none of the antagonists used in the present study, except spiperone, had any significant effect on plasma prolactin secretion. These findings suggest that m-CPP-induced prolactin secretion is mediated by stimulation of 5-HT1C receptors while corticosterone secretion may be mediated either by an antagonistic effect at 5-HT3 receptor subtype or by nonserotonergic mechanisms. Alternatively, enhancement of corticosterone secretion by the 5-HT antagonists when administered alone may be responsible for their failure to block m-CPP-induced corticosterone secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
给大鼠注射间氯苯哌嗪[m-CPP,一种5-羟色胺(5-HT)激动剂]会增加催乳素和皮质酮的血浆浓度。用不同剂量的利坦色林(5-HT1C/5-HT2拮抗剂)、ICS 205-930和MDL-72222(5-HT3拮抗剂)、碘氰吲哚洛尔或CG361A(β肾上腺素能受体拮抗剂)以及舒必利(5-HT1A/5-HT2拮抗剂)预处理,并不会减弱m-CPP诱导的催乳素血浆浓度升高。相反,用不同剂量的美替拉酮(5-HT1/5-HT2拮抗剂)、普萘洛尔(对5-HT1A、5-HT1B和5-HT1C位点也有结合亲和力的β肾上腺素能受体拮抗剂)、美舒麦角和米安色林(5-HT1C/5-HT2拮抗剂)预处理,会减弱m-CPP诱导的血浆催乳素升高。另一方面,m-CPP诱导的皮质酮浓度升高仅通过低剂量米安色林和高剂量舒必利预处理而减弱。当在没有m-CPP的情况下给药时,美替拉酮、美舒麦角、利坦色林、ICS 205-930以及高剂量的米安色林、舒必利和普萘洛尔会增加血浆皮质酮分泌。另一方面,本研究中使用的拮抗剂,除舒必利外,均对血浆催乳素分泌无显著影响。这些发现表明,m-CPP诱导的催乳素分泌是由5-HT1C受体的刺激介导的,而皮质酮分泌可能由5-HT3受体亚型的拮抗作用或非5-羟色胺能机制介导。或者,5-HT拮抗剂单独给药时增强皮质酮分泌可能是它们未能阻断m-CPP诱导的皮质酮分泌的原因。(摘要截断于250字)